Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric disease. Transcend is developing TSND-201 (methylone), a rapid-acting neuroplastogen, as a treatment for post-traumatic stress disorder (PTSD) and other CNS indications. Transcend recently presented positive interim Phase 2a in patients with PTSD, which demonstrated rapid, robust, and durable therapeutic effects in PTSD and a signal for rapid, robust, and durable improvements in depressive symptoms. Transcend’s leadership team has made pivotal contributions to 13 successful NDAs (including recent MDD approval), $3.5B in M&A, and significant public company value creation.